Navigation Links
LSUHSC awarded $2 million dollar grant to prevent pneumonia linked to immune deficiency
Date:7/13/2010

New Orleans, LA Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia (PCP), which can be a complication of HIV/AIDS. It can also be a complication of cancer, organ or bone marrow transplantation, as well as the chronic use of corticosteroids or other medications that affect the immune system.

Pneumocystis carinii pneumonia remains an important clinical problem and although there is a well-known relationship between CD4 cell count and the risk of Pneumocystis carinii infection, defense mechanisms against it are not fully understood. Dr. Kolls and his research team will study the role of a subset of CD4 cells which he believes are missing in Pneumocystis carinii infection and which when restored, produce an effective immune response to the infection. These are the T-helper cells, Th1, Th2, and Th17. The research funded under this grant will determine the role of interleukin-23 and interleukin-12 in regulating Th1 immunity to Pneumocystis carinii, and the team hopes to show that by vaccinating genetically engineered mice with CD4+ T-cells belonging to any of these T-cell subsets, immunity will be sufficient to protect against PCP.

"This research will define the types of T-cells that are needed to prevent this life-threatening infection," notes Dr. Kolls. "It is our hope that vaccines can activate these cells to prevent or treat PCP."

According to the Centers for Disease Control and Prevention, Pneumocystis pneumonia (PCP), which is caused by Pneumocystis jirovecii (formerly P. carinii), is frequently the first serious illness encountered by HIV-infected persons. During the early years of the AIDS epidemic, PCP was the AIDS-defining illness for as many as two thirds of patients in the United States. Although a decline in incidence of PCP occurred during the era of highly active antiretroviral therapy (HAART), PCP remains the most common serious opportunistic illness in HIV-infected persons. Patients in the developing world without access to PCP prophylaxis or antiretroviral drugs remain at high risk, and PCP continues to develop in certain groups in industrialized countries. There is also a potential for drug resistance to develop.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC awarded patent for compound inhibiting cancer and other diseases
2. LSUHSC research identifies key contributor to Alzheimers disease process
3. LSUHSC student awarded top national honor for diabetes research
4. LSUHSC public health researcher finds reason for weight gain
5. LSUHSC research describes function of key protein in cancer spread
6. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
7. LSUHSC research helps link schizophrenia to specific DNA region
8. LSUHSCs Bazan awarded ARRA grant to preserve vision
9. LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
10. Grant supports LSUHSC research on how like cell receptor systems determine very different functions
11. LSUHSC researchers working to prevent diabetic neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... ... January 23, 2017 , ... Edward Buckler, ... recipient of the National Academy of Sciences Prize in Food and Agriculture Sciences. ... , The annual National Academy of Sciences (NAS) Prize in Food and Agriculture ...
(Date:1/24/2017)... 2017 According to a new ... (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, ... Biotech Companies, CRO) - Global Forecast to 2021", published ... Model Market for the forecast period of 2016 to ... Million by 2021 from USD 73.3 Million in 2016, ...
(Date:1/24/2017)... Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... an underwriting agreement with Rodman & Renshaw, a unit ... sole book running manager and representative of several underwriters, under ... firm commitment basis a minimum of 2,105,264 shares of ... purchase a minimum of 1,052,632 shares of common stock ...
(Date:1/23/2017)... 2017   Enteris BioPharma, Inc. , announced today ... Sanofi to leverage Enteris, proprietary and patented oral ... an oral formulation of one of Sanofi,s preclinical stage ... Executive Officer and Executive Chairman of Enteris BioPharma, remarked, ... tremendous value our Peptelligence platform program offers in the ...
Breaking Biology Technology: